Biotech · Private company
Neuraptive Therapeutics Inc.
Track this companyFree. Adds Neuraptive Therapeutics Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials51 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- NTX-001 (PEG-Fusion)Phase 3 · Peripheral Nerve Injury Upper LimbClinicalTrials.gov · fetched Nov 12, 2026
- NTX-001Phase 2 · Facial ParalysisClinicalTrials.gov · fetched Nov 12, 2026
- NTX-001Phase 2 · Peripheral Nerve InjuriesClinicalTrials.gov · fetched Nov 12, 2026
- NTX-001Peripheral Nerve Transections, Acute or Planned in Upper Extremity and Facial NervesClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- This Study Will Evaluate the Effectiveness of NTX-001, a Surgical Nerve Repair Product When Used in People With Upper Extremity Nerve Lacerations.PHASE3 · RECRUITING · started Feb 10, 2025ClinicalTrials.gov NCT06616025 · fetched Nov 12, 2026
- A Study of NTX-001 in the Treatment and Prevention of Facial Paralysis Requiring Surgical Repair.PHASE2 · TERMINATED · started Jul 12, 2022ClinicalTrials.gov NCT05293522 · fetched Nov 12, 2026
- Safety and Efficacy of NTX-001 Compared to SOC in Acute Single Peripheral Nerve InjuriesPHASE2 · COMPLETED · started Sep 25, 2020ClinicalTrials.gov NCT04572906 · fetched Nov 12, 2026
- Conversion of Seddon III Nerve Injury to Seddon I/II Nerve InjuryPHASE1 · TERMINATED · started May 1, 2016ClinicalTrials.gov NCT03236064 · fetched Nov 12, 2026
- NTX-001 to Repair Peripheral Nerve Transection(s)AVAILABLEClinicalTrials.gov NCT05565846 · fetched Nov 12, 2026